Achilles Therapeutics Sells TRACERx And MAP Assets To AstraZeneca For $12M, Transferring Tumor Data And Samples; Concludes Strategic Review With Plans For Workforce And Board Reductions
Achilles Therapeutics Sells TRACERx And MAP Assets To AstraZeneca For $12M, Transferring Tumor Data And Samples; Concludes Strategic Review With Plans For Workforce And Board Reductions
阿基里斯治療公司以1200萬美元將TRACERx和MAP資產出售給阿斯利康，轉移腫瘤數據和樣本；結束戰略審查並計劃裁減員工和董事會成員。
Achilles Therapeutics Sells TRACERx And MAP Assets To AstraZeneca For $12M, Transferring Tumor Data And Samples; Concludes Strategic Review With Plans For Workforce And Board Reductions
阿基里斯治療公司以1200萬出售TRACERx和MAP資產給阿斯利康，轉移腫瘤數據和樣本；結束戰略評審，計劃裁減員工和董事會成員。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。